PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

EQT Life Sciences closes neuro fund at hard cap

EQT Life Sciences has held the final close of its LSP Dementia Fund, raising approximately €260 million in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million. 

EQT Life Sciences has held the final close of its LSP Dementia Fund, raising approximately €260 million in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million. 

The fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies across the spectrum of neurodegenerative diseases.
  
The LSP Dementia Fund investment team is led by Philip Scheltens, MD, PhD, professor emeritus at Amsterdam University Medical Center and a renowned dementia researcher, having (co)authored over 1100 scientific publications. 

The other partners in the investment team are Felice Verduyn-van Weegen, MBA, Cillian King, PhD, and Arno de Wilde, MD, PhD, MBA. 

The fund is supported by a broad range of investors including the Alzheimer’s Association, the world’s largest charity and advocacy organisation in the field, insurance companies, the European Investment Fund, and several global pharmaceutical companies – including from Asia and the US. Other investors include endowments, foundations, and other private wealth investors.
 
The fund intends to invest in 10 to 15 companies in total. Having made its first investment in NewAmsterdam Pharma (Nasdaq: NAMS), which focuses on cardiovascular and Alzheimer’s disease, in January 2021, the fund has since invested in four companies: Muna Therapeutics (Alzheimer’s disease and Parkinson’s disease), AviadoBio (Frontotemporal Dementia (FTD) and Amyotrophic lateral sclerosis (ALS)), Nobi (smart care solutions in nursing homes) and QurAlis (FTD and ALS).

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured